Opportunities to Optimize Cancer Policies Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Jun

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer

First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors

CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC

Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer